Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations
NCT ID: NCT05607641
Last Updated: 2022-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
424 participants
INTERVENTIONAL
2021-07-07
2022-05-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery
NCT00266786
Parecoxib vs. Dexketoprofen for the Management of Pain After Cesarean Section.
NCT04847024
Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride
NCT01902134
Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy
NCT02642718
Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery
NCT00161577
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).
Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).
Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Neospastil, solution for injection then Neospastil, film-coated tablets
Neospastil, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).
Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).
Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).
Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Neospastil, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).
Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.
Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.
Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The estimated need to use the first dose of the IMP no later than 8 hours after the completion of minimally invasive surgical abdominal and pelvic operations.
3. Immediately before randomization, there is a moderate to severe pain associated with minimally invasive surgical abdominal and pelvic operation (the overall assessment of pain at rest is 4-8 points inclusively in 11-point NRS).
4. At the time of minimally invasive surgery, the patient's condition corresponded to the class I-III of general anesthesia risk according to the classification of the American Society of Anesthesiologists (ASA).
5. The patient is able to adequately assess his/her condition and fill in yourself the patient's diary.
6. The patient agrees to participate in the clinical trial and fulfill all the requirements of the trial and has signed the informed consent form.
7. According to the investigator, IMP is an adequate tactic for postoperative analgesia.
Exclusion Criteria
2. The patient has another disease/condition that requires constant use of non-topical analgesics and/or anti-inflammatory agents or, in the opinion of the investigator, disturbs the patient's perception of postoperative pain.
3. The need for postoperative treatment in the intensive care unit for any reason.
4. Active peptic ulcer, recent gastrointestinal bleeding or perforation, history of peptic ulcer or gastrointestinal bleeding.
5. History of bronchial asthma.
6. Severe heart failure (class III-IV according to NYHA).
7. Severe liver failure (including an increase in the activity of alanine aminotransferase and/or aspartate aminotransferase in the blood more than three times the upper limit of normal).
8. Moderate to severe renal failure (blood creatinine concentration \> 160 μmol/l).
9. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, including blood coagulation disorders and high risk of bleeding.
10. Dehydration with the risk of kidney failure due to a decrease in the volume of circulating blood.
11. Benign prostatic hyperplasia of the ΙΙ and ΙΙΙ degree.
12. Cardiovascular diseases in which an increase in heart rate may be undesirable (for example, atrial fibrillation, tachycardia \[pulse rate at rest \> 100 bpm\], severe arterial hypertension), as well as an artificial pacemaker.
13. Glaucoma.
14. Signs of intestinal obstruction and/or history of megacolon.
15. Anemia (hemoglobin concentration \< 90 g/l) and/or leukopenia (leukocyte count \< 3.2x109/l) according to the results of preoperative laboratory examination.
16. Diseases or conditions that make it impossible to take drugs orally in accordance with the Clinical Trial Protocol and/or disrupt their absorption in the gastrointestinal tract.
17. The use of drugs prohibited by the Clinical Trial Protocol before the start of study treatment and/or the need to use drugs prohibited by the Clinical Trial Protocol during the investigational treatment.
18. Mental disorder/illness, which, in the opinion of the investigator, may prevent the patient from fulfilling all the requirements of the trial.
19. Pregnancy or lactation.
20. Within 30 days prior to randomization, the use of a drug or medical product in another clinical trial.
21. The patient has already been previously randomized in this trial.
Criteria to start the 2nd stage of treatment, the patient had to meet the criteria for switching to IMP for oral administration:
* pain level of 4-6 points at movements according to the 11-point Numerical Rating Scale (NRS) (7 points were allowed, if pain level at rest did not exceed 6 points according to 11-point NRS);
* no more than 12 hours have passed since the last use of IMP;
* oral analgesic use is an adequate tactic for postoperative analgesia.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Darnitsa Pharmaceutical Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regional municipal nonprofitable institution "Chernivtsi regional clinical hospital", urological department
Chernivtsi, , Ukraine
Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №1
Dnipro, , Ukraine
Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №2
Dnipro, , Ukraine
Communal noncomercial enterprise of the Kharkiv Regional Council "Regional Medical Clinical Center of Urology and Nephrology named after V.I. Shapovala", urology department №5
Kharkiv, , Ukraine
Communal noncomercial enterprise "Kyiv City Clinical Hospital #3" Kyiv City Council (Kyiv City State Administration), urological department
Kyiv, , Ukraine
Medical Center of the LLC "Harmony of Beauty"
Kyiv, , Ukraine
State Institution "Institute of Urology of the National Academy of Medical Sciences of Ukraine", I Urological Department
Kyiv, , Ukraine
Communal noncomercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Hospital", department of urology
Lviv, , Ukraine
Municipal Non-profit Enterprise "Lviv Clinical Hospital for Emergency Medical Care"
Lviv, , Ukraine
Communal noncomercial enterprise "City Clinical Hospital #10" Odesa City Council, urological department #2
Odesa, , Ukraine
Medical-diagnostic center" Zakarpattya center of surgical innovations" Astra-med "of limited liability company" Clinic of healthy family "Astramed"
Uzhhorod, , Ukraine
Communal noncomercial enterprise" Vinnytsia City Clinical Hospital" Mother and Child Center", department of gynecology with minimally invasive operations
Vinnytsia, , Ukraine
Limited Liability Company "Innomed Center of Endosurgery"
Vinnytsia, , Ukraine
Communal noncomercial enterprise "City Hospital of Emergency and Ambulance" of Zaporizhia City Council, Department of Surgery with the Center for Gastrointestinal Bleeding
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KPF07-T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.